Explore All 9664 Add-on Acquisition Information Technology Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | November 4, 2014 |
| Target | Definiens AG |
| Sector | Information Technology |
| Buyer(s) | AstraZeneca |
| Sellers(s) |
Cipio Partners
Gilde Healthcare |
| Deal Type | Add-on Acquisition |
| Deal Value | 150M USD |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1992 |
| Sector | Life Science |
| Employees | 83,100 |
| Revenue | 54.1B USD (2024) |
AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.
| Deal Context for Buyer | # |
|---|---|
| Overall | 9 of 23 |
| Sector: Information Technology | 1 of 1 |
| Type: Add-on Acquisition | 7 of 17 |
| Country: Germany | 1 of 1 |
| Year: 2014 | 2 of 2 |
| Size (of disclosed) | 19 of 19 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-08-20 |
AstraZeneca - Ethyol
United States AstraZeneca - Ethyol is a cytoprotective drug indicated as an adjuvant therapy to reduce the incidence of xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-11-06 |
Myalept
United States Myalept™ (metreleptin for injection) is an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy. |
Sell | $325M |
| Category | Secondary Investor |
|---|---|
| Founded | 2003 |
| Size | Small |
| Type | Sector Agnostic |
Cipio Partners is an investment management firm focused on secondary investments, as well as early and later-stage venture capital transactions. Sectors of interest include technology, media, and communications. Cipio Partners was formed in 2003 and is based in Munich, Germany.
| Deal Context for Seller | # |
|---|---|
| Overall | 52 of 68 |
| Sector: Information Technology | 8 of 9 |
| Type: Add-on Acquisition | 25 of 35 |
| Country: Germany | 17 of 22 |
| Year: 2014 | 2 of 2 |
| Size (of disclosed) | 4 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-06-23 |
MyOptique Group
London, United Kingdom MyOptique Group Ltd. is an online optical segment with a full offering covering all three major segments in the eyewear market prescription glasses, contact lenses and sunglasses via its Glasses Direct, Sunglasses Shop, LensOn and MyOptique websites. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-02-09 |
Voltage Security
Cupertino, California, United States Voltage Security, Inc. is an enterprise security company and global leader in enterprise data protection for data residing both inside and outside the cloud. Voltage solutions provide cloud-scale encryption and simplified key management for protecting sensitive information wherever it is stored and processed, on-premise or in private and public clouds. |
Sell | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1982 |
| PE ASSETS | 2.6B EUR |
| Size | Large |
| Type | Sector Focused |
Gilde Healthcare is a specialist private equity and venture investor focused on the healthcare sector. The Firm's buyout group targets majority investments throughout Europe (preference for Germany, the Netherlands, Belgium, Austria or Switzerland) and has a focus on healthcare providers, suppliers and service providers active in the healthcare market. The Firm's venture group looks to invest in early stage medtech, diagnostics, digital health and therapeutics companies throughout North America and Europe. Gilde Healthcare was established in 1982 and is headquartered in Utrecht, Netherlands.
| Deal Context for Seller | # |
|---|---|
| Overall | 14 of 35 |
| Sector: Information Technology | 1 of 4 |
| Type: Add-on Acquisition | 8 of 17 |
| Country: Germany | 5 of 7 |
| Year: 2014 | 5 of 6 |
| Size (of disclosed) | 8 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-10-07 |
Levicept
Sandwich, United Kingdom Levicept is a biopharmaceutical company focused solely on the preclinical and clinical development of p75NTR-Fc as treatment for osteoarthritis and chronic pain. Levicept was founded in 2012 and is based in Sandwich, United Kingdom. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-12-18 |
Pieris
Boston, United States Pieris is a clinical-stage biotechnology company applying its proprietary Anticalin technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need. Pieris was founded in 2000 and is based in Boston, Massachusetts. |
Sell | - |
